Personalis Q3 revenue beats estimates on higher test volume; suspends forecast pending Tempus AI merger
PSNL•Personalis reported Q3 revenue of $25.6 million, above the $21.85 million consensus estimate, while posting a $33.8 million net loss. The company suspended financial guidance because of its pending merger with Tempus AI.
1. Revenue tops estimates
Personalis reported Q3 revenue of $25.6 million, compared with the $21.85 million analyst consensus. Net loss was $33.8 million, and loss per basic share was $0.32.
2. Growth drivers and outlook
The company attributed revenue growth to higher clinical test volume, expanded Medicare coverage, increased pharma testing services and population sequencing. Personalis said it would not provide financial guidance because of its pending merger with Tempus AI. It also launched Real-Time Variant Tracker as a supplemental offering to its NeXT Personal MRD test.
